Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Zhihao Gu, Yong Yan, Hequan Yao, Kejiang Lin & Xuanyi Li. (2022) Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present). Expert Opinion on Therapeutic Patents 32:10, pages 1097-1122.
Read now
Read now
Francesco Mincione, Alessio Nocentini & Claudiu T. Supuran. (2021) Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opinion on Drug Discovery 16:10, pages 1209-1225.
Read now
Read now
Emanuela Berrino & Claudiu T Supuran. (2019) Rho-kinase inhibitors in the management of glaucoma. Expert Opinion on Therapeutic Patents 29:10, pages 817-827.
Read now
Read now
Paolo Guglielmi, Simone Carradori, Cristina Campestre & Giovanna Poce. (2019) Novel therapies for glaucoma: a patent review (2013-2019). Expert Opinion on Therapeutic Patents 29:10, pages 769-780.
Read now
Read now
Ramon Guerra de Oliveira, Fabiana Sélos Guerra, Cláudia dos Santos Mermelstein, Patrícia Dias Fernandes, Isadora Tairinne de Sena Bastos, Fanny Nascimento Costa, Regina Cely Rodrigues Barroso, Fabio Furlan Ferreira & Carlos Alberto Manssour Fraga. (2018) Synthesis and pharmacological evaluation of novel isoquinoline N-sulphonylhydrazones designed as ROCK inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 33:1, pages 1181-1193.
Read now
Read now
Articles from other publishers (49)
Vinicius Moraes de Paiva Roda, Rafael André da Silva, Paula Veloso Siqueira, Gabriela Jesus Lustoza-Costa, Gabriélla Malheiros Moraes, Monique Matsuda, Dânia Emi Hamassaki & Marinilce Fagundes Santos. (2024) Inhibition of Rho kinase (ROCK) impairs cytoskeletal contractility in human Müller glial cells without effects on cell viability, migration, and extracellular matrix production. Experimental Eye Research 238, pages 109745.
Crossref
Crossref
Robert A Sykes, Karla B Neves, Rhéure Alves-Lopes, Ilaria Caputo, Kirsty Fallon, Nigel B Jamieson, Anna Kamdar, Assya Legrini, Holly Leslie, Alasdair McIntosh, Alex McConnachie, Andrew Morrow, Richard W McFarlane, Kenneth Mangion, John McAbney, Augusto C Montezano, Rhian M Touyz, Colin Wood & Colin Berry. (2023) Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy. European Heart Journal - Cardiovascular Pharmacotherapy 9:4, pages 371-386.
Crossref
Crossref
Junghoon Lee, Hwancheol Son, Soo Woong Kim & Min Chul Cho. (2023) Chronic treatment with a combination of hepatocyte growth factor and JNK inhibitor ameliorates cavernosal veno-occlusive dysfunction: a rat model of cavernous nerve injury. The Journal of Sexual Medicine.
Crossref
Crossref
Lloyd R. Kopecny, Brendon W.H. Lee & Minas T. Coroneo. (2023) A systematic review on the effects of ROCK inhibitors on proliferation and/or differentiation in human somatic stem cells: A hypothesis that ROCK inhibitors support corneal endothelial healing via acting on the limbal stem cell niche. The Ocular Surface 27, pages 16-29.
Crossref
Crossref
Yehudis Rosenwasser, Irene Berger & Zvi G. Loewy. (2022) Therapeutic Approaches for Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. Pathogens 11:12, pages 1513.
Crossref
Crossref
Jianjian Shi & Lei Wei. (2022) Rho Kinases in Embryonic Development and Stem Cell Research. Archivum Immunologiae et Therapiae Experimentalis 70:1.
Crossref
Crossref
Qingfang Li, Yuan Cheng, Zhe Zhang, Zhenfei Bi, Xuelei Ma, Yuquan Wei & Xiawei Wei. (2022) Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3. Clinical and Translational Medicine 12:10.
Crossref
Crossref
Tingting Liao, Jingjing Deng, Wenjuan Chen, Juanjuan Xu, Guanghai Yang, Mei Zhou, Zhilei Lv, Sufei Wang, Siwei Song, Xueyun Tan, Zhengrong Yin, Yumei Li & Yang Jin. (2022) Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation. Cancers 14:19, pages 4709.
Crossref
Crossref
Lei Wei & Jianjian Shi. (2022) Insight Into Rho Kinase Isoforms in Obesity and Energy Homeostasis. Frontiers in Endocrinology 13.
Crossref
Crossref
Johannes Menzel-Severing & Gerd Geerling. (2022) Descemet-Stripping ohne Transplantat bei Fuchsʼscher endothelialer Hornhautdystrophie?. Klinische Monatsblätter für Augenheilkunde 239:06, pages 760-766.
Crossref
Crossref
Clare Mills, Sandra A. Hemkemeyer, Zerin Alimajstorovic, Chantelle Bowers, Malihe Eskandarpour, John Greenwood, Virginia Calder, A. W. Edith Chan, Paul J. Gane, David L. Selwood, Karl Matter & Maria S. Balda. (2022) Therapeutic Validation of GEF-H1 Using a De Novo Designed Inhibitor in Models of Retinal Disease. Cells 11:11, pages 1733.
Crossref
Crossref
Fabian A Mendoza & Sergio A Jimenez. (2022) Serine/threonine kinase inhibition as antifibrotic therapy: transforming growth factor-β and Rho kinase inhibitors. Rheumatology 61:4, pages 1354-1365.
Crossref
Crossref
Olmo Martín-Cámara, Ángel Cores, Pilar López-Alvarado & J. Carlos Menéndez. (2021) Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis disfunction by the RhoA/ROCK pathway. European Journal of Medicinal Chemistry 225, pages 113742.
Crossref
Crossref
Seohyun Kim, Seong A. Kim, Jihoon Han & In-San Kim. (2021) Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential. International Journal of Molecular Sciences 22:23, pages 12916.
Crossref
Crossref
Upendarrao Golla, Melanie A. Ehudin, Charyguly Annageldiyev, Zheng Zeng, Diwakar Bastihalli Tukaramrao, Anna Tarren, Abhijit A. Date, Irina Elcheva, Arthur Berg, Shantu Amin, Thomas P. LoughranJr.Jr., Mark Kester, Dhimant Desai, Sinisa Dovat, David Claxton & Arati Sharma. (2021) DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. Cancers 13:19, pages 4889.
Crossref
Crossref
Yingchun Xiang, Yumiao Niu, Yacong Xie, Shishuo Chen, Feng Zhu, Weida Shen & Ling‐Hui Zeng. (2021) Inhibition of RhoA/Rho kinase signaling pathway by fasudil protects against kainic acid‐induced neurite injury. Brain and Behavior 11:8.
Crossref
Crossref
Tadeu L. Montagnoli, Jaqueline S. da Silva, Susumu Z. Sudo, Aimeé D. Santos, Gabriel F. Gomide, Mauro P. L. de Sá & Gisele Zapata-Sudo. (2021) ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension. Cells 10:7, pages 1648.
Crossref
Crossref
Wakako Kawarazaki & Toshiro Fujita. (2021) Role of Rho in Salt-Sensitive Hypertension. International Journal of Molecular Sciences 22:6, pages 2958.
Crossref
Crossref
Audrey J. Weber & Jeremy H. Herskowitz. (2021) Perspectives on ROCK2 as a Therapeutic Target for Alzheimer’s Disease. Frontiers in Cellular Neuroscience 15.
Crossref
Crossref
Gregory Moloney, Daniel Garcerant Congote, Nino Hirnschall, Tasneem Arsiwalla, Ana Luiza Mylla Boso, Nicholas Toalster, Mario D'Souza & Raj N. Devasahayam. (2021) Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study. Cornea 40:3, pages 320-326.
Crossref
Crossref
Islam M. Saadeldin, Hammed A. Tukur, Riyadh S. Aljumaah & Ramya A. Sindi. (2021) Rocking the Boat: The Decisive Roles of Rho Kinases During Oocyte, Blastocyst, and Stem Cell Development. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Min Chul Cho, Junghoon Lee, Juhyun Park & Soo Woong Kim. (2021) Restoration of Cavernous Veno-Occlusive Function through Chronic Administration of a Jun-Amino Terminal Kinase Inhibitor and a LIM-Kinase 2 Inhibitor by Suppressing Cavernous Apoptosis and Fibrosis in a Rat Model of Cavernous Nerve Injury: A Comparison with a Phosphodiesterase Type 5 Inhibitor. The World Journal of Men's Health 39:3, pages 541.
Crossref
Crossref
Andrea Lopez‐Lopez, Carmen M. Labandeira, Jose L. Labandeira‐Garcia & Ana Muñoz. (2020)
Rho kinase inhibitor fasudil reduces
l
‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease
. British Journal of Pharmacology 177:24, pages 5622-5641.
Crossref
Crossref
Edd Ricker, Akanksha Verma, Rossella Marullo, Sanjay Gupta, Chao Ye, Tania Pannellini, Michela Manni, Wayne Tam, Giorgio Inghirami, Olivier Elemento, Leandro Cerchietti & Alessandra B. Pernis. (2020) Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Scientific Reports 10:1.
Crossref
Crossref
Lisa McKerracher, Robert Shenkar, Matthew Abbinanti, Ying Cao, Amy Peiper, James K. Liao, Rhonda Lightle, Thomas Moore, Nicholas Hobson, Carol Gallione, Joerg Ruschel, Janne Koskimäki, Romuald Girard, Kenneth Rosen, Douglas A. Marchuk & Issam A. Awad. (2019) A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. Translational Stroke Research 11:3, pages 365-376.
Crossref
Crossref
Jordi Pujols, Samuel Peña-Díaz, Irantzu Pallarès & Salvador Ventura. (2020) Chemical Chaperones as Novel Drugs for Parkinson’s Disease. Trends in Molecular Medicine 26:4, pages 408-421.
Crossref
Crossref
Jin-Ha Yoon, Thi-Thao-Linh Nguyen, Van-An Duong, Kwang-Hoon Chun & Han-Joo Maeng. (2020) Determination of KD025 (SLx-2119), a Selective ROCK2 Inhibitor, in Rat Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Pharmacokinetic Application. Molecules 25:6, pages 1369.
Crossref
Crossref
Shalaka Mulherkar & Kimberley F. Tolias. (2020) RhoA-ROCK Signaling as a Therapeutic Target in Traumatic Brain Injury. Cells 9:1, pages 245.
Crossref
Crossref
M. G. Matera, C. P. Page, L. Calzetta, P. Rogliani & M. Cazzola. (2019) Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacological Reviews 72:1, pages 218-252.
Crossref
Crossref
Lei Wei, Michelle Surma, Yang Yang, Sarah Tersey & Jianjian Shi. (2019) ROCK2 inhibition enhances the thermogenic program in white and brown fat tissue in mice. The FASEB Journal 34:1, pages 474-493.
Crossref
Crossref
Sean Porazinski, Ashleigh Parkin & Marina Pajic. 2020. Tumor Microenvironment. Tumor Microenvironment
99
127
.
Mario Cazzola, Paola Rogliani & Maria Gabriella Matera. (2019) The future of bronchodilation: looking for new classes of bronchodilators. European Respiratory Review 28:154, pages 190095.
Crossref
Crossref
Lanying Zhao, Yueshan Li, Yujiao Wang, Zeen Qiao, Zhuang Miao, Jiao Yang, Luyi Huang, Chenyu Tian, Linli Li, Danian Chen & Shengyong Yang. (2019)
Discovery of 4
H
-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models
. Journal of Medicinal Chemistry 62:23, pages 10691-10710.
Crossref
Crossref
Kelsey M. Greathouse, Benjamin W. Henderson, Erik G. Gentry & Jeremy H. Herskowitz. (2019) Fasudil or genetic depletion of ROCK1 or ROCK2 induces anxiety-like behaviors. Behavioural Brain Research 373, pages 112083.
Crossref
Crossref
Akrit Sodhi, Tao Ma, Deepak Menon, Monika Deshpande, Kathleen Jee, Aumreetam Dinabandhu, Jordan Vancel, Daoyuan Lu & Silvia Montaner. (2019) Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema. Journal of Clinical Investigation 129:11, pages 4593-4608.
Crossref
Crossref
Soo Woong Kim, Junghoon Lee, Juhyun Park, Ji Sun Chai, Sohee Oh, Jae-Seung Paick & Min Chul Cho. (2019) Combination of LIM-kinase 2 and Jun Amino-terminal Kinase Inhibitors Improves Erectile Function in a Rat Model of Cavernous Nerve Injury. Urology 131, pages 136-143.
Crossref
Crossref
Stanley Sau Ching Wong, Un Man Lee, Xiao-Min Wang, Sookja Kim Chung & Chi Wai Cheung. (2019) Role of DLC2 and RhoA/ROCK pathway in formalin induced inflammatory pain in mice. Neuroscience Letters 709, pages 134379.
Crossref
Crossref
Jiří Voller, Lenka Zahajská, Lucie Plíhalová, Jana Jeřábková, David Burget, Andreea Csilla Pataki, Vladimír Kryštof, Marek Zatloukal, Jan Brábek, Daniel Rösel, Václav Mik, Martin Tkáč, Tomáš Pospíšil, Tomáš Gucký, Karel Doležal & Miroslav Strnad. (2019) 6-Substituted purines as ROCK inhibitors with anti-metastatic activity. Bioorganic Chemistry 90, pages 103005.
Crossref
Crossref
Haicheng Tang, Wenwen Du, Yongqian Jiang, Hongmiao Li, Hongjian Bo & Shu Song. (2019)
Retracted
: Upregulated expression of ROCK1 promotes cell proliferation by functioning as a target of miR‐335‐5p in non‐small cell lung cancer
. Journal of Cellular Physiology.
Crossref
Crossref
Paul Lingor, Markus Weber, William Camu, Tim Friede, Reinhard Hilgers, Andreas Leha, Christoph Neuwirth, René Günther, Michael Benatar, Magdalena Kuzma-Kozakiewicz, Helen Bidner, Christiane Blankenstein, Roberto Frontini, Albert Ludolph & Jan C. Koch. (2019) ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Frontiers in Neurology 10.
Crossref
Crossref
Renato Fraga Righetti, Tabata Maruyama dos Santos, Leandro do Nascimento Camargo, Luciana Ritha Cássia Rolim Barbosa Aristóteles, Silvia Fukuzaki, Flávia Castro Ribas de Souza, Fernanda Paula Roncon Santana, Marcus Vinicius Rodrigues de Agrela, Maysa Mariana Cruz, Maria Isabel Cardoso Alonso-Vale, Isabella Santos Genaro, Beatriz Mangueira Saraiva-Romanholo, Edna Aparecida Leick, Milton de Arruda Martins, Carla Máximo Prado & Iolanda de Fátima Lopes Calvo Tibério. (2018) Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice. Frontiers in Pharmacology 9.
Crossref
Crossref
Jinkun Wen, Dandan Tan, Lixia Li, Xianghai Wang, Mengjie Pan & Jiasong Guo. (2018) RhoA regulates Schwann cell differentiation through JNK pathway. Experimental Neurology 308, pages 26-34.
Crossref
Crossref
Jan Christoph Koch, Lars Tatenhorst, Anna-Elisa Roser, Kim-Ann Saal, Lars Tönges & Paul Lingor. (2018) ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacology & Therapeutics 189, pages 1-21.
Crossref
Crossref
A. Samdani & Umashankar Vetrivel. (2018) POAP: A GNU parallel based multithreaded pipeline of open babel and AutoDock suite for boosted high throughput virtual screening. Computational Biology and Chemistry 74, pages 39-48.
Crossref
Crossref
Yong Zhou. (2018) Most Good, Least Harm: Isoform-Specific Targeting of ROCK in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology 58:4, pages 421-422.
Crossref
Crossref
Yi-Shuai Zhang, Li-Jing Tang, Hua Tu, Shi-Jing Wang, Bin Liu, Xiao-Jie Zhang, Nian-Sheng Li, Xiu-Ju Luo & Jun Peng. (2018) Fasudil ameliorates the ischemia/reperfusion oxidative injury in rat hearts through suppression of myosin regulatory light chain/NADPH oxidase 2 pathway. European Journal of Pharmacology 822, pages 1-12.
Crossref
Crossref
Katharina Schrade, Jessica Tröger, Adeeb Eldahshan, Kerstin Zühlke, Kamal R. Abdul Azeez, Jonathan M. Elkins, Martin Neuenschwander, Andreas Oder, Mohamed Elkewedi, Sarah Jaksch, Karsten Andrae, Jinliang Li, Joao Fernandes, Paul Markus Müller, Stephan Grunwald, Stephen F. Marino, Tanja Vukićević, Jenny Eichhorst, Burkhard Wiesner, Marcus Weber, Michael Kapiloff, Oliver Rocks, Oliver Daumke, Thomas Wieland, Stefan Knapp, Jens Peter von Kries & Enno Klussmann. (2018) An AKAP-Lbc-RhoA interaction inhibitor promotes the translocation of aquaporin-2 to the plasma membrane of renal collecting duct principal cells. PLOS ONE 13:1, pages e0191423.
Crossref
Crossref
Mario Cazzola, Paola Rogliani, Luigino Calzetta, Davide Lauro, Clive Page & Maria Gabriella Matera. (2017) Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends in Pharmacological Sciences 38:10, pages 940-951.
Crossref
Crossref
Anna-Elisa Roser, Lars Tönges & Paul Lingor. (2017) Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis. Frontiers in Aging Neuroscience 9.
Crossref
Crossref